Septerna has filed a notice of an exempt offering of securities to raise $150,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Septerna is raising $150,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Jeffrey Finer played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Septerna
Septerna is on a mission to make the promise of future GPCR medicines a reality for patients. Combining the latest advances in biochemical, structural and computational drug discovery approaches, we have built an industrialized platform to precisely control and modulate GPCR biology and pharmacology to discover and develop new high-impact medicines. With our Native Complex platform, we are opening a new frontier in GPCR small molecule discovery technologies to expand the druggable GPCR landscape. We are always looking for talented scientists, drug hunters, and business professionals to join our mission to launch a new era of GPCR medicines. If you’re passionate about innovation, energized by teamwork, and fueled by the desire to change patient lives, join us and become a part of the Septerna story! .
To learn more about Septerna, visit http://www.septerna.com/
Contact:
Jeffrey Finer, Chief Executive Officer
650-338-3533
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.